Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash from Operations (2020 - 2023)

Candel Therapeutics' Cash from Operations history spans 4 years, with the latest figure at 7422000.0 for Q4 2023.

  • For Q4 2023, Cash from Operations fell 7.8% year-over-year to 7422000.0; the TTM value through Dec 2023 reached 34244000.0, down 8.99%, while the annual FY2024 figure was 27023000.0, 21.09% up from the prior year.
  • Cash from Operations for Q4 2023 was 7422000.0 at Candel Therapeutics, up from 8808000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1505000.0 in Q3 2020 and bottomed at 10819000.0 in Q1 2023.
  • The 4-year median for Cash from Operations is 6995500.0 (2021), against an average of 6628714.29.
  • The largest annual shift saw Cash from Operations tumbled 358.07% in 2021 before it rose 6.14% in 2023.
  • A 4-year view of Cash from Operations shows it stood at 3416000.0 in 2020, then plummeted by 53.34% to 5238000.0 in 2021, then tumbled by 31.44% to 6885000.0 in 2022, then decreased by 7.8% to 7422000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Cash from Operations are 7422000.0 (Q4 2023), 8808000.0 (Q3 2023), and 7195000.0 (Q2 2023).